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Abstract
Background: The human endometrium is an important site for contact between the host and pathogens
ascending the reproductive tract, and thus plays an important role in female reproductive tract immunity. Previous
work in our laboratory has suggested that Toll-like receptors (TLRs) are involved in endometrial epithelial
recognition of pathogens and that ligation of endometrial TLRs results in the production of cytokines and
chemokines important for both immune and reproductive functions of the endometrium. We have also
demonstrated cyclic regulation of TLR3 mRNA and protein expression in human endometrium, suggesting that
steroid hormones might play a role in the expression and function of TLR3. In this study, the effects of 17beta-
estradiol (E2) and progesterone (P) on TLR3 expression and function in endometrial cell lines were investigated.
Methods: Endometrial epithelial cell lines were cultured and examined for the presence of TLR3 and hormone
receptors by endpoint RT-PCR. For hormonal studies, cells were pre-treated with ethanol vehicle, 10^(-8) M E2,
and/or 10^(-7) M P. For antagonist assays, cells were treated with the ER antagonist, ICI 182, 780, or the PR
antagonist, RU486, for two hours prior to treatment with hormones. Following hormone or hormone/antagonist
pre-treatment, cells were stimulated with vehicle, the synthetic TLR3 ligand, polyinosinic-polycytidylic acid (Poly
I:C), a negative dsDNA control, or a positive control. Cytokine and chemokine production post-stimulation was
measured by ELISA. The effects of E2 and P on TLR3 mRNA and protein expression were measured using Real
Time RT-PCR and FACS analysis, respectively.
Results: Stimulation of TLR3-expressing cells with the synthetic TLR3 ligand, Poly I:C, resulted in the production
of cytokines and chemokines important for endometrial function and regulation. Suppression of Poly I:C-induced
cytokine and chemokine production by cells treated with 10^(-8) M E2, but not cells treated with 10^(-7) M P,
was observed in endometrial epithelial cell lines expressing TLR3 and estrogen receptor alpha (ERalpha). The
effects of E2 were not observed on cells which did not express ERalpha or in cells pre-treated with the ER
antagonist, ICI 182, 780. Treatment with E2 did not affect TLR3 mRNA or protein expression. However,
treatment with E2 did suppress cytokine and chemokine production resulting from TLR3 stimulation with Poly
I:C, suggesting that E2 modulates TLR3 function.
Conclusion: The data presented in this study are the first indication that E2 can markedly alter the innate
immune response to dsRNA, providing a previously unreported process by which E2 can alter immune responses.
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The human endometrium coordinates the reproductive
events leading to embryo implantation and pregnancy.
The surface and glandular epithelium of the endometrium
is an important site of contact between the host and sev-
eral pathogens ascending the reproductive tract, including
gonorrhea, chlamydia, human immunodeficiency virus
(HIV), cytomegalovirus (CMV), and herpes simplex virus
(HSV), as well as allogeneic sperm and the semi-alloge-
neic embryo. Thus, the endometrial epithelium must tol-
erate contact with sperm and tissue invasion by the
embryo, yet actively mount immune responses to patho-
gens in order to prevent infection.
A component of the endometrial epithelial response to
pathogens is thought to be the elaboration of cytokines,
which can activate both innate and acquired immune
responses. Cytokines also play an essential role in regulat-
ing normal endometrial functions including embryo
implantation, epithelial proliferation and shedding, and
regulation of steroid hormone production[1-4]. The
endometrial epithelium and stroma are rich sources of
cytokine expression and important targets for cytokine
action[1]. The importance of cytokines in the
endometrium is further exemplified by the association
between abnormal cytokine expression and endometrial
dysfunctions including infertility, recurrent miscarriage,
and endometriosis[1,5,6]. For example, Interleukin-6 (IL-
6) and Interleukin-8 (IL-8) have been shown to be ele-
vated in the peritoneal fluid of women with endometrio-
sis, but the reason for this abnormal cytokine expression
has not been determined [7-10].
Cyclic changes in endometrial cytokine expression suggest
modulation of cytokine expression by estradiol (E2) and
progesterone (P)[3,11]. In vitro studies have shown that E2
and/or P can either inhibit or stimulate expression of spe-
cific cytokines. Specifically, Pottratz and colleagues dem-
onstrated suppression of cytokine-stimulated IL-6 mRNA
by E2 in HeLa cells transfected with estrogen receptor
(ER)[12]. Suppression of IL-6 was also observed by Tabib-
zadeh and colleagues in IL-1α-induced stromal cells[13].
Girasole and colleagues have demonstrated similar results
using E2 on mouse cell lines and stromal cell lines[14]. P,
at high concentrations, has been shown by Kelly and col-
leagues to reduce the level of IL-8 in the endometrium[3].
However, Tseng and colleagues found IL-6 to be up-regu-
lated by E2 in stromal cells[15], while von Wolff and col-
leagues and Rifas and colleagues suggested hormones do
not regulate IL-6[16,17]. Thus, studies examining the
influence of steroid hormones on cytokine expression and
production in the human have been somewhat conflict-
ing and the impact of cytokine control by steroid hor-
mones on mucosal immunity in the endometrium has
not been elucidated[3,12-17]. The observed differences in
the influence of E2 on cytokine expression may depend, in
part, on the ligand-receptor signaling system responsible
for the induction of cytokine expression and production.
Toll-like Receptors (TLRs) play an important role in recog-
nition of pathogens and induction of several gene expres-
sion patterns during infection. TLRs are innate pattern
recognition receptors (PRRs) characterized by amino-ter-
minal leucine-rich repeats (LRRs) and carboxy-terminal
Toll/IL-1 receptor (TIR) signaling domains [18-20] (for
review see 20 and 21). TLRs recognize unique pathogen
associated molecular patterns (PAMPs) to initiate and
shape adaptive immune responses [21-24]. For example,
TLR3 has been shown to bind double-stranded RNA
(dsRNA), a product of most viral life cycles, and TLR4 rec-
ognizes bacterial lipopolysaccharide (LPS). TLR expres-
sion in the endometrial epithelium has been documented
and endometrial TLRs, such as TLR3, have been shown to
produce cytokines and chemokines including IL-6 and IL-
8 upon TLR ligation [25-28]. Therefore, since TLR activa-
tion induces cytokine production and cytokines are
required for proper endometrial function, TLRs may play
a significant role in influencing and shaping immunolog-
ical outcomes in the endometrium.
We and others have previously demonstrated expression
of TLR3 mRNA and protein in the endometrium [25-28].
We also showed that TLR3 in the endometrium responded
to dsRNA by producing specific cytokines and chemok-
ines[26]. Although double-stranded RNA-activated pro-
tein kinase (PKR) has been shown to bind dsRNA, we
found that the response to dsRNA in the endometrial epi-
thelial cell line, RL95-2, was dependent on TLR3 by utiliz-
ing small inhibitory RNAs against TLR3[26]. Our findings
established a requirement for TLR3 in the response to
dsRNA in the RL95-2 cells, eliminating the possibility that
PKR is responsible for the dsRNA response in endometrial
epithelial cells[26]. Endometrial TLR3 expression has also
been demonstrated to be cycle-dependent, with an
approximately ten-fold up-regulation of TLR3 mRNA and
protein during the mid- and late secretory phase of the
menstrual cycle[26]. However, the role of steroid hor-
mones in the regulation of TLR3 expression and/or func-
tion has not been examined. In this study, we investigated
the role of E2 and P in the modulation of endometrial
TLR3 expression and function.
Methods
Cell lines and cell culture
The endometrial epithelial cell lines, AN3-CA, HEC-1-A,
KLE, and RL95-2, and the breast adenocarcinoma cell line,
MCF7, were obtained from the American Type Culture
Collection (ATCC) (Manassas, VA). KLE and RL95-2 cells
were maintained in phenol red-free DMEM-F12, HEC-1-A
cells in McCoy's 5a, AN3-CA cells in MEM, and MCF7Page 2 of 15
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were supplemented with 2 mM L-glutamate and 50 µg/ml
gentamicin (American Pharmaceutical Partners, Inc.,
Schaumburg, IL). MCF7 cells were additionally supple-
mented with 1 mM sodium pyruvate, 1 mM non-essential
amino acids (NEAA), and 0.15 mg/ml sodium bicarbo-
nate. All media contained 5% fetal bovine serum (FBS)
(US Bio-Technologies, Inc., Parkerfield, PA). Forty-eight
hours prior to experiments, media was replaced with CD-
F12, a phenol red-free DMEM/F12 containing charcoal/
dextran treated FBS (Hyclone, Logan, UT) and the previ-
ously mentioned additives specific for each cell line.
Adherent cell lines were harvested using 0.05% trypsin/
0.53 mM EDTA in HBSS. Unless otherwise indicated, all
reagents were obtained from Invitrogen (Carlsbad, CA).
Hormone treatment and cell stimulation
17β-estradiol (E2) and progesterone (P) (Calbiochem,
San Diego, CA) were resuspended in ethanol to make a 1
mM stock solution of E2 and P. Prior to experiments, E2
and P stock solutions were diluted to the indicated con-
centrations using CD-F12. E2 and P concentrations were
determined by performing a dose response. The chosen
concentrations demonstrated the highest level of cytokine
and chemokine suppression after stimulation, based on
preliminary experiments, and were also physiologically
relevant. Cells were examined for presence of hormone
receptors by endpoint RT-PCR using primers listed in
Table 1 prior to performing each experiment. Following
48 hours culture in CD-F12, cells were plated at 0.2 × 106
cells/well/ml in 12 well plates. The following day (~12
hours), CD-F12 media was aspirated and replaced with
CD-F12 media containing either 0.001% ethanol vehicle
(V), 10-8 M E2, 10-7 M P, or a combination of 10-8 M E2 and
10-7 M P. Triplicate wells were used for each hormone
treatment condition and stimulation condition. For hor-
mone receptor antagonist experiments, cells were pre-
treated for 2 hours with CD-F12 media containing V, 10-6
M ICI 182, 780 or 10-6 M RU486 (Tocris, St. Louis, MO).
Following antagonist treatment, media was aspirated and
replaced with CD-F12 containing V, 10-8 M E2, or 10-7 M
P, with antagonist vehicle, 10-6 M ICI 182, 780, or 10-6 M
RU486. Hormone and antagonist combinations are indi-
cated for in each figure demonstrating hormone and/or
antagonist results. Triplicate wells were used for each con-
dition. After 48 hours treatment, the triplicate wells were
stimulated with ligand. Supernatants and/or cells for each
well were harvested after 18 hours of stimulation. Cells
were stimulated with the synthetic TLR3 ligand, polyinos-
inic-polycytidylic acid (Poly I:C, 10 µg/ml) (Amersham
Pharmaceutical Biotech, Piscataway, NJ), the double-
stranded DNA negative control, polydeoxyinosinic-deox-
ycytidylic acid (Poly dI:dC, 10 µg/ml) (Amersham Phar-
maceutical Biotech, Piscataway, NJ), or the positive
control, phorbol-12-myristate-13-acetate (Calbiochem,
San Diego, CA) plus Ionomycin (Calbiochem, San Diego,
CA) (PMA/I, 100 ng/ml/500 ng/ml). Supernatants were
centrifuged at 1400 rpm for 8 minutes at 4°C, transferred
to fresh tubes, and stored at -20°C until use. Cells were
washed once with 1× PBS prior to use.
Enzyme linked immunosorbent assay (ELISA)
IL-6, IL-8, and Interferon-inducible protein 10 (IP-10)
matched antibody pairs were purchased from either Bio-
Legend (San Diego, CA) or BD Biosciences (San Diego,
CA), and ELISA was performed according to manufac-
turer's instructions with 100 µl of cell free supernatant. IL-
6 detection limit was 5 pg/ml, IL-8 was 8 pg/ml, and IP-10
was 10 pg/ml (the lowest standard used in each standard
curve). Absorbance at 450 nm was read with the SPEC-
TRAMax 190 microplate spectrophotometer, and results
were analyzed by SOFTMax Pro software (Molecular
Devices, Sunnyvale, CA). Sample concentrations were
determined by interpolation from the standard curve.
Triplicate samples for each treatment condition were ana-
lyzed in each experiment. Readings for the triplicate treat-
Table 1: List of primers.
Primer Name Forward Primer Reverse Primer Base Primer Anneal
TLR1 CTATACACCAAGTTGTCAGC GTCTCCAACTCAGTAAGGTG 220 61
TLR2 GTACCTGTGGGGCTCATTGT CTGCCCTTGCAGATACCATT 191 62
TLR3 GATCTGTCTCATAATGGCTTG GACAGATTCCGAATGCTTGTG 305 60
TLR4 ACAACCTCCCCTTCTAACC AACTCTGGATGGGGTTTCCT 201 61
TLR5 CTAGCTCCTAATCCTGATG CCATGTGAAGTCTTTGCTGC 438 59
TLR6 AGGTGCCTCCATTATCCTCA GAATCCATTTGGGAAAGCAG 211 59
TLR7 CTCCCTGGATCTGTACACCTGTGA CTCCCACAGAGCCTTTTCCGGAGCT 551 55
TLR8 GTCCTGGGGATCAAAGAGGGAAGAG CTCTTACAGATCCGCTGCCGTAGCC 581 55
TLR9 TTCCCTGTAGCTGCTGTCC ACAGCCAGTTGCAGTTCACC 207 58
TLR10 GGCCAGAAACTGTGGTCAAT CTGCATCCAGGGAGATCAGT 199 61
ER-Alpha TGCCAAGGAGACTCGCTACT CTGGCGCTTGTGTTTCAAC 276 55
ER-Beta TCAGCTTGTGACCTCTGTGG TGTATGACCTGCTGCTGGAG 178 56
PR-A GGTCTACCCGCCCTATCTCA GGCTTGGCTTTCATTTGGAA 397 55
PR-B GAGGGGGCAGTGGAACTCAG AGGGGAACTGTGGCTGTCGT 293 55Page 3 of 15
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was calculated. Statistical analysis between treatment con-
ditions was performed as described below. All experi-
ments were performed a minimum of three times.
RNA isolation
Endometrial epithelial cell lines were grown to confluence
in 12 well plates and total RNA was isolated using the
RNAqueous kit (Ambion, Austin, TX) per manufacturer's
instructions. RNA was treated with 11 µl of Turbo DNase
buffer, 2 µl of Turbo DNase, and 22 µl of Turbo DNase
inactivation reagent (Ambion, Austin, TX). RNA was
quantified using the RiboGreen® RNA Quantitation kit
(Molecular Probes, Eugene, OR), and fluorescence was
measured using a 485 nm excitation filter and a 535 nm
emission filter on a Fusion™ Universal Microplate Reader
(Perkin-Elmer, Wellesley, MA). RNA concentrations were
interpolated from a standard curve. Samples were meas-
ured in triplicate.
End Point Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR) and Electrophoresis
A total of 100 ng of RNA was used to synthesize cDNA
using the random primers provided in the ImProm-II™
Reverse Transcriptase System (Promega, Madison, WI).
Briefly, 100 ng of RNA was denatured at 65°C for 15 min-
utes and immediately placed on ice for 5 minutes. RNA
was combined with master mix containing 4 µl ImProm-
II 5× reaction buffer, 2 µl 25 mM MgCl, 1 µl 10 mM dNTP
mix, 1 µl random primers, 0.5 µl RNasin, and water. Mas-
ter mix was prepared with or without AMV reverse tran-
scriptase (RT) in a total reaction volume of 20 µl. The
reaction was run using an Eppendorf® Master Gradient
Thermocycler (Brinkman, Westbury, NY). Polymerase
chain reaction (PCR) using gene specific primers was per-
formed using 1 µl cDNA in 25 µl total reaction volume.
PCR amplification was performed using Eppendorf® Mas-
terTaq Polymerase (Brinkman, Westbury, NY). Primers for
TLRs 1–10, ERα, PRB, and PRT were obtained from the lit-
erature and are listed in Table 1[25,28,29]. Primers for
ERβ, also listed in Table 1, were designed using Primer3
software http://www-genome.wi.mit.edu/cgi-bin/primer/
primer3_www.cgi (Whitehead Institute for Biomedical
Research, Cambridge, MA). Loading dye (5 µl) was added
to the reaction and 10 µl of sample was run on a 2% aga-
rose 3:1 (Amresco, Solon, OH) gel to separate PCR prod-
ucts. Gels were stained with SYBR® Green (BioWhittaker,
Rockland, ME) for 45 minutes and visualized by ultravio-
let transillumination at 302 nm. Digital images were
obtained using a GelLogic 100 (Kodak, Rochester, NY).
Real time RT-PCR
Real time RT-PCR was performed using cDNA synthesized
as described for end point RT-PCR. cDNA was combined
with primer/probe sets and Taqman® Universal PCR Mas-
ter Mix (Applied Biosystems, Inc., Foster City, CA).
Primer/probe sets for TLR3, ERα, and hypoxanthine pho-
phoribosyltransferase (HPRT) were purchased and
designed using TaqMan Gene Expression Assays™
(Applied Biosystems, Inc., Foster City, CA). Real time
assays were run on an ABI 7000 (Applied Biosystems, Inc.,
Foster City, CA). Samples were normalized internally
using the cycle threshold (CT) of the housekeeping gene,
HPRT, as follows: ∆CT = (CT TLR3 or CT ERα) - (CT
HPRT). Quantitative values for ERα mRNA are demon-
strated using ∆CT, where the samples with the highest
quantitative level of ERα mRNA have the lowest value and
the samples with the lowest quantitative level of ERα
mRNA have the highest value. For analysis of quantitative
TLR3 mRNA values, the mean CT of RNA from untreated
cells (Norm 1) was set to a relative quantity (RQ) value of
1 using the ∆∆CT calculated as follows: ∆∆CT = mean
∆CT(Norm 1) - mean ∆CT(Norm 1) and RQ = 2(-1*∆∆CT).
All other samples were compared to the mean RQ value
for the untreated cells (Norm 1) using the following equa-
tion: ∆∆CT = ∆CT(sample) - mean ∆CT(Norm 1). RQ val-
ues were calculated as follows: RQ = 2(-1*∆∆CT).
Protein Lysates and Western Blot Analysis
For preparation of protein lysates from endometrial epi-
thelial cell lines for western blot analysis, cells were lysed
by adding ice-cold RIPA lysis buffer (50 mM Tris, 150 mM
NaCl, 50 mM NaF, 1 mM Na4P2O7·10 H2O, 0.1% DOC,
1.0% NP-40, 50 µl Na3VO4, and 100 µl Halt Protease
Inhibitor Cocktail (Pierce Biotechnology, Inc, Rockford,
IL)). After 30 min on ice with shaking, the lysates were
centrifuged at 15000 × g for 10 min at 4°C. Supernatants
were stored at -80°C until use. For western blot analysis,
protein concentrations were determined using the BCA
Protein Assay (Pierce Biotechnology, Inc, Rockford, IL).
Equal amounts of unboiled protein were loaded onto a 4–
20% Tris-HCl Precast Gel (BioRad) with 10 µl of sample
or Blue Ranger marker (Pierce Biotechnology, Inc, Rock-
ford, IL), and transferred to two identical 0.45 µM PVDF
membranes (Millipore, Billerica, MA). The membranes
were washed in Tris-buffered saline containing 0.05%
Tween 20 (TBS-T) and non-specific binding sites were
blocked by immersing the membrane in block reagent
(1:7.5 mL Sea Block·TBS blocking buffer) (Pierce Biotech-
nology, Inc, Rockford, IL) for 1 hour at room temperature
on a shaker. The membranes were then washed with TBS-
T. One of two identical membranes was incubated over-
night at 4°C with the isotype antibody in blocking buffer.
The other membrane was incubated overnight at 4°C with
ERα clone H-184 in blocking buffer. ERα clone H-184 was
generously provided by Dr. Mark Hannink (University of
Missouri-Columbia, Columbia, MO). Membranes were
then washed and incubated with secondary antibody for
1 hour at room temperature. After incubation, the mem-
branes were washed in TBS-T. Bound antibodies werePage 4 of 15
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Femto; Pierce Biotechnology, Inc, Rockford, IL) as recom-
mended by the manufacturer's instructions. For exposure
(10 seconds, 30 seconds, 1 min, 5 min, and up to 1 h) we
used CL-XPosure™ Film (Pierce Biotechnology, Inc, Rock-
ford, IL).
Flow Cytometry
Cells were plated in 12 well plates and grown to conflu-
ence in CD-F12 with or without hormones. After 72
hours, cells were harvested, counted, and 0.5 × 106 cells
were labeled with either PE-labeled mIgG1α hTLR3 anti-
body (clone TLR3.7) (eBioscience, San Diego, CA) or PE-
labeled mIgG1 isotype control (BD Biosciences, San
Diego, CA). For intracellular staining, cells were fixed
using Cytofix/Cytoperm buffer (BD Biosciences, San
Diego, CA), and all washes and incubations were per-
formed in the saponin-containing Perm/Wash buffer (BD
Biosciences, San Diego, CA). Cells were analyzed using a
Fluorescence-Activated Cell Sorter (FACScan) instrument
and analysis was performed using CellQuest software (BD
Biosciences, San Diego, CA). Ten thousand cells were
counted, and viability was determined by generating for-
ward scatter (FSC) versus side scatter (SSC) density plots
and setting the gate to exclude dead cells. Histogram plots
included only gated live cells. Markers indicating TLR3
positive cells were set so that less than 10% of isotype con-
trol cells were included in the positive marker.
Statistical analysis
Mean values for treatment conditions in triplicate were
compared using one-way analysis of variance (ANOVA)
and the Tukey post-hoc test to determine statistical signif-
icance. Differences were considered to be statistically sig-
nificant at P < 0.05.
Results
Endometrial epithelial cell lines express TLR3 and steroid 
hormone receptors
To examine the presence of TLR3, ERα, ERβ, PRA, and PRB
in endometrial cell lines, mRNA was subjected to RT-PCR.
The human breast adenocarcinoma cell line, MCF7, was
used as a positive control for expression of mRNA coding
for estrogen receptor (ER) and progesterone receptor (PR)
[30-32]. We have previously demonstrated expression of
TLR3 mRNA in RL95-2 cells[26]. We confirmed expres-
sion of TLR3 mRNA in the RL95-2 cells, and demon-
strated expression of TLR3 mRNA in the cell lines HEC-1-
A, KLE, and MCF7 (Table II). Expression of ER and/or PR
has been previously demonstrated in the HEC-1-A, KLE,
MCF7, and RL95-2 cells [30-34]. Receptor expression in
these cell lines was confirmed and receptor expression was
documented in AN3-CA cells. As summarized in Table II,
many of our cell lines express detectable levels of mRNA
for TLR3 and hormone receptors. We observed that the
band intensity for all cell lines expressing hormone recep-
tors was high, with intensity for the MCF7 cells being the
highest. To determine if the differences observed by end-
point RT-PCR were due to quantitative differences in ERα
mRNA expression, we subjected cDNA synthesized from
100 ng RNA from each of the cell lines to Real Time RT-
PCR. As demonstrated in Figure 1A, our cell lines express
varying quantities of ERα mRNA. The AN3-CA and MCF7
cells expressed the highest levels of ERα mRNA, with val-
ues significantly greater than values for the RL95-2, KLE,
and HEC-1A cells. The RL95-2 and KLE cells expressed the
second highest levels of ERα mRNA, which were signifi-
cantly lower than values for the AN3-CA and MCF7 cells,
but greater than values for the HEC-1A cells, which did
not express ERα mRNA. Thus, the results in Figure 1A con-
firm the endpoint RT-PCR results shown in Table 2 and
demonstrate differential expression of ERα mRNA in
endometrial and breast epithelial cell lines.
To determine whether hormone treatment altered expres-
sion of ERα mRNA, we subjected the RL95-2 cell line to
hormone treatment and analyzed ERα mRNA by Real
Time RT-PCR. Hormone concentrations were determined
by dose response as described in Methods. As demon-
strated in Figure 1B, hormone treatment does not alter
levels of ERα mRNA in the RL95-2 cells.
In addition to endpoint and Real Time RT-PCR, we also
analyzed our cell lines for presence of ERα protein. The
MCF7 breast epithelial cell line was used as a positive con-
trol (Figure 1C, lanes 3 and 4). All cell lines, with the
exception of the HEC-1A cells and high passage RL95-2
cells (Figure 1C, lane 2), express ERα protein (Figure 1C
and data not shown). As shown in Figure 1C, MCF7 cells
(lanes 3 and 4) express a greater amount of ERα protein
than the RL95-2 cells (Figure 1C, lane 1), confirming the
Table 2: Epithelial cells express TLR3 and hormone receptor 
mRNA.
Cell Line TLR3 ERα ERβ PRA PRB
AN3 CA - + + + +
HEC-1-A + - + - -
KLE + + + + +
MCF7 + + + + +
RL95-2 + + + + +
cDNA synthesized from 100 ng RNA was subjected to end-point PCR 
with the indicated primer sets (see Table 1). The endometrial 
epithelial cell lines, AN3-CA, HEC-1-A, KLE, and RL95-2 were scored 
for hormone receptor expression on the basis of a visible band at the 
appropriate size. The breast adenocarcinoma cell line, MCF7, served 
as a positive control for hormone receptor expression. Cell lines 
were compared to the RL95-2 cells for expression of TLR3.Page 5 of 15
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ERα expression with high passage, which has been previ-
ously documented [37]. Due to the ability of RL95-2 cells
to lose ERα expression with high passage, receptor pres-
ence had to be verified prior to experiments.
17β-estradiol suppresses cytokine and chemokine 
production in Poly I:C-stimulated RL95-2 cells
We have previously demonstrated production of IL-6, IL-
8, and the chemokine IP-10 after stimulation of RL95-2
cells with the synthetic dsRNA, Poly I:C[26]. We have also
demonstrated that the response to Poly I:C in the RL95-2
cells is dependent on the expression of TLR3[26]. Since
expression of TLR3 mRNA and protein was shown to be
cyclically regulated[26], we performed experiments to
examine whether E2 and P may influence TLR3 expression
and/or function. A dose response was performed for E2
and P to determine the concentration of hormone to be
used. The concentrations chosen, 10-8 M E2 and 10-7 M P,
resulted in the greatest degree of cytokine and chemokine
suppression (data not shown) and are also physiologi-
cally relevant[3,35]. Cells were stimulated with Poly I:C,
PMA/I, or Poly dI:dC in triplicate. PMA/I directly activates
intracellular signaling mechanisms leading to cytokine
expression and was used as a positive control[26]. Poly
dI:dC, a dsDNA analogue of Poly I:C, does not act as a
TLR3 ligand and was used as a negative control to demon-
strate the specificity of Poly I:C for TLR3[26]. Superna-
tants were collected and examined for production of IL-6,
IL-8, and IP-10. Experiments were repeated at least three
times to ensure reproducibility. RL95-2 cells treated with
E2 showed significant suppression of IL-6, IL-8, and IP-10
protein secretion upon stimulation with Poly I:C in com-
parison to vehicle-treated controls and P-treated samples
Endometrial epithelial cells express ERα mRNA and proteinFigure 1
Endometrial epithelial cells express ERα mRNA and protein. (A) cDNA was synthesized from 100 ng of RNA isolated 
and subjected to quantitative Real Time RT-PCR using primer/probe sets for HPRT and ERα. Delta CT was calculated as fol-
lows: ERα CT – HPRT CT. ERα quantities ± SD from samples in triplicate are shown, with cell lines expressing the highest lev-
els of ERα mRNA demonstrating the lowest Delta CT value. The Delta CT value representative of zero expression of ERα is 
shown (black bar). Statistical analysis was determined using ANOVA (P < 0.05). One asterisk (*) represents statistical signifi-
cance as compared to bars with no asterisk. Two asterisks (**) represents statistical significance as compared to (*) and bars 
with no asterisk. (B) cDNA was synthesized from 100 ng of RNA isolated and subjected to quantitative Real Time RT-PCR 
using primer/probe sets for HPRT and ERα. Average ERα quantities (RQ values) ± SD from samples in triplicate are shown by 
using the housekeeping gene, HPRT, to normalize samples. (C) Protein lysates from endometrial and breast epithelial cell lines 
were collected and 10 µg of protein was analyzed for presence of ERα protein (67 kD) by Western Blot. Samples shown are as 
follows: (1) RL95-2 cells positive for ERα mRNA by endpoint RT-PCR, (2) RL95-2 cells negative for ERα mRNA by endpoint 
RT-PCR, (3) and (4) MCF7 positive control.Page 6 of 15
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cantly suppressed PMA/I-induced IL-6 production, but
did not significantly suppress IL-8 (Figure 2A). PMA/I
treatment did not induce production of IP-10 (Figure 2C).
Suppression of PMA/I response by E2 has been previously
documented[12,36]. The significance of the suppression
is notable considering the significant proliferative effect of
E2 on RL95-2 cells as compared to vehicle-treated cells
(Figure 2D). P did not induce significant proliferation of
RL95-2 cells in comparison to vehicle-treated cells (Figure
2D). The response to the synthetic dsRNA, Poly I:C, was
specific because stimulation with the synthetic dsDNA,
Poly dI:dC, had no effect. These results suggest that E2, but
not P, significantly suppresses proinflammatory and anti-
viral cytokine responses upon Poly I:C stimulation of
RL95-2 cells.
Effects of E2 and P on cytokine and chemokine production and proliferation in RL95-2 cellsFigure 2
Effects of E2 and P on cytokine and chemokine production and proliferation in RL95-2 cells. RL95-2 cells were 
plated at 0.2 × 106 cells/well/ml and maintained in charcoal/dextran-treated DMEM/F12 (CD-F12) for 48 hours prior to exper-
iments. Media was replaced with media containing either 10-8 M E2 or 10-7 M P as determined by dose response. Cells remained 
in hormone-containing media for 66 hours total and were stimulated with vehicle, Poly I:C (10 µg/ml), or PMA/I (10 ng/ml and 
500 ng/ml) 18 hours prior to harvest. A total of 100 µl of cell-free supernatant was used to detect IL-6, IL-8, and IP-10 by ELISA 
(A, B, and C). RL95-2 cells were plated at 0.2 × 106 cells/well/ml, harvested, and counted after 18 hours of stimulation with 
vehicle (black bars) or Poly I:C (10 µg/ml, gray bars). The mean of three cell counts of triplicate wells counted for each time 
point from one experiment is shown (D). Experiments were performed using triplicate wells for each treatment condition and 
repeated three times. Representative data is shown. Error bars indicate standard deviation of three samples. Statistical signifi-
cance (*) was determined by one-way ANOVA and the Tukey post-hoc test (P < 0.05).Page 7 of 15
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protein expression in RL95-2 cells
Previous work in our laboratory has demonstrated cyclic
variation of TLR3 mRNA and protein expression in
human endometrium[26], suggesting the possibility that
some of the E2 suppression of Poly I:C-stimulated
cytokine production might be due to E2 regulation of
TLR3 expression. To examine this possibility, RNA col-
lected in triplicate from RL95-2 cells treated with ethanol
vehicle, 10-8 M E2, or 10-7 M P was used to examine TLR3
mRNA expression by real time RT-PCR. E2 and P did not
significantly alter TLR3 mRNA expression (P > 0.05) as
compared to vehicle-only controls (Figure 3A and 3B).
The results in this in vitro model system suggest that nei-
ther E2 nor P directly regulates TLR3 gene transcription.
Protein expression was examined by Fluorescent-Acti-
vated Cell Sorter (FACS) analysis of RL95-2 cells treated
with ethanol vehicle, 10-8 M E2, or 10-7 M P in triplicate.
We had previously shown that RL95-2 cells express TLR3
intracellularly[26]. In these experiments, the intracellular
expression of TLR3 in RL95-2 cells was not altered by
treatment with E2 and P as compared to vehicle-treated
controls (Figure 3C). Protein expression remained unal-
tered in response to E2 or P treatment for up to 7 days
(data not shown). The lack of alteration in TLR3 mRNA
Effects of E2 and P on TLR3 mRNA and protein expressionFigure 3
Effects of E2 and P on TLR3 mRNA and protein expression. cDNA synthesized using 100 ng of RNA from RL95-2 cells 
treated with 10-8 M E2 or 10-7 M P for 66 hours was used to detect expression levels of TLR3 mRNA by real-time RT-PCR. 
Data are shown as average cycle threshold ± SD from samples in triplicate for TLR3 and HPRT (A). Average TLR3 quantities 
(RQ values) ± SD from samples in triplicate are shown by using the housekeeping gene, HPRT, to normalize samples (B). RL95-
2 cells were harvested after 72 hours of treatment with 10-8 M E2 or 10-7 M P and labeled with PEαTLR3.7 mAb in order to 
detect intracellular TLR3 protein by FACS analysis. PE-conjugated mIgG1 was used as an isotype control (C). Experiments 
were repeated three times. Data representative of three experiments are shown.Page 8 of 15
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observed suppression of cytokine production is not due to
transcriptional or translational regulation of TLR3.
Estrogen receptor is required for suppression of cytokine 
and chemokine production by 17β-estradiol in poly I:C-
stimulated endometrial epithelial cells
To determine if similar effects could be observed in other
endometrial epithelial cell lines, the cell lines KLE, HEC-
1-A, and AN3 CA were used. As expected, the TLR3-nega-
tive, hormone receptor-positive cell line, AN3 CA, did not
respond to Poly I:C (data not shown). Treatment of KLE
cells with E2 and P resulted in a non-significant decrease
in production of IL-6 and a significant decrease in produc-
tion of IP-10 (Figure 4A), which was expected since KLE
cells express TLR3, ER, and PR (Table II). The observed
decrease in IL-6 production in the KLE cells treated with E2
or P was not statistically significant (P = 0.165) and may
be due to the described defects in nuclear ER trafficking in
the cell line[34]. The KLE cell line produced background
levels of IL-8 too high for observation of a Poly I:C-
induced effect (data not shown). A suppressive effect from
hormone treatment was not observed in the HEC-1-A cells
(Figure 4B), which express TLR3 and ERβ, but do not
express ERα, PRA, or PRB (Table II). Our results, therefore,
suggest that ERα must be present for suppression of
cytokine or chemokine production. Finally, RL95-2 cells
have been reported to lose ERα expression with continued
passage in culture[37]. In our study, consistent with previ-
ous reports, RL95-2 cells lacking ERα did not exhibit sup-
pressive effects after E2 treatment (Figure 1C and data not
shown) and receptors had to be verified in the RL95-2
cells prior to each experiment to ensure reliable results.
Thus, suppression of cytokine and chemokine production
by E2 in endometrial epithelial cells may require ERα.
Suppression of cytokine and chemokine production by 
estrogen in Poly I:C-stimulated RL95-2 cells is ER-
dependent
Since treatment with E2 and P did not affect TLR3 mRNA
or protein expression in the RL95-2 cells (Figure 3A, 3B,
and 3C), but did affect TLR3-induced cytokine and chem-
okine production, and hormone receptor-negative cell
lines do not show a suppressive response, we postulated
that the suppressive effect may be hormone receptor-
dependent. To determine if the suppression of cytokine
and chemokine production in RL95-2 cells was hormone
receptor-dependent, we utilized the hormone receptor
antagonists, ICI 182, 780 and RU486. For the no-antago-
nist controls, cells were treated with ethanol vehicle, E2, or
P (representative data in Figure 2). Treatment with the ER
antagonist, ICI 182, 780, restored cytokine and chemok-
ine levels in E2-treated samples to those of vehicle-treated
controls (Figure 5A). RU486 had no restorative effect on
E2-treated samples, as expected (Figure 5B). Since suppres-
sion was not seen in the no-antagonist, P-treated samples,
treatment with the PR antagonist, RU486, had no effect
(Figure 5B). These results are not due to a suppression of
cytokine and chemokine production in the vehicle-treated
samples by the antagonists themselves because the antag-
onists caused a reduction in cell number for all antago-
nist-treated samples (data not shown). Thus, our results
confirm that E2 suppresses cytokine and chemokine pro-
Effects of E2 and P on endometrial epithelial cells expressing or not expressing hormone receptorsFigure 4
Effects of E2 and P on endometrial epithelial cells 
expressing or not expressing hormone receptors. KLE 
(A) and HEC-1-A (B) cells were plated at 0.2 × 106 cells/well/
ml and maintained in CD-F12 for 48 hours prior to experi-
ments. Media was replaced with media containing either 10-8 
M E2 or 10-7 M P. Cells remained in hormone-containing 
media for a total of 66 hours. 18 hours prior to harvest of 
supernatants, cells were stimulated with the vehicle, Poly I:C 
(10 µg/ml), or PMA/I (10 ng/ml and 500 ng/ml). ELISA was 
performed with 100 µl of cell-free supernatant. Data repre-
sentative of three experiments are shown. Error bars indi-
cate standard deviation of three samples. Statistical 
significance (*) was determined by one-way ANOVA and the 
Tukey post-hoc test (P < 0.05).Page 9 of 15
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receptor-dependent manner.
MCF7 cells express functional TLR3
To determine whether the observed hormone effect was
characteristic of only endometrial epithelial cells, or if the
suppressive effect occurred in a different epithelial cell
line, we utilized the breast epithelial adenocarcinoma,
MCF7. MCF7 cells have been shown to express ER and PR
and respond to E2 and P treatment [30-32]. MCF7 cells
were examined for expression of TLR mRNA. We found
that MCF7 cells express TLR2, TLR3, TLR5, and TLR6
(Table II, Figure 6A, and data not shown). For detection of
TLR3 in the MCF7 cells, the RL95-2 cells were used as a
positive control. The amplified band in the RL95-2 and
MCF7 cells was of the appropriate size for TLR3 (Figure
6A). To determine if TLR3 expressed in these cells was
functional, MCF7 cells were stimulated with Poly I:C,
PMA/I, the TLR4 ligand lipopolysaccharide (LPS), or Poly
dI:dC in triplicate. Supernatants were collected and exam-
ined for production of IL-6, IL-8, and IP-10. MCF7 cells,
as expected, did not respond to stimulation with LPS or
Poly dI:dC (Figure 6B and data not shown). MCF7 cells
did produce significant amounts of IL-8 and IP-10 after
stimulation with Poly I:C and IL-8 after stimulation with
PMA/I (Figure 6B and data not shown). However, the
MCF7 cells did not produce IL-6. Our results demonstrate
that MCF7 cells express functional TLR3 and produce
cytokines and chemokines upon stimulation with Poly
I:C.
17β-estradiol and progesterone suppress cytokine and 
chemokine production in Poly I:C-stimulated MCF7 cells in 
a hormone receptor-dependent manner
Since MCF7 cells express functional TLR3, we examined
whether E2 and/or P suppress production of cytokines and
chemokines in Poly I:C-stimulated MCF7 cells. The
response to dsRNA was specific, as the MCF7 cells did not
respond to stimulation with the synthetic dsDNA, Poly
dI:dC. As expected, the cells did not produce IL-6 upon
stimulation with Poly I:C. Cells treated with E2 and P
exhibited a significant suppressed response to Poly I:C
and PMA/I in comparison to vehicle only controls (Figure
7A). This is in direct contrast to the RL95-2 cells, in which
significant cytokine and chemokine suppression when
treated with P was not observed (Figure 2A, 2B, and 2C).
MCF7 cells demonstrated suppression of TLR3-induced
cytokine and chemokine production in response to E2 and
P treatment (Figure 7A) and we did not observe changes
in TLR3 mRNA or protein expression in these cells (data
not shown). Therefore, we wanted to determine if the sup-
pressive responses were hormone receptor-dependent, as
in the RL95-2 cells. ICI 182, 780 and RU486 have previ-
ously been shown to be effective on MCF7 cells by other
investigators [38-40]. Treatment of E2-treated wells with
ICI 182, 780 and P-treated wells with RU486 restored
cytokine and chemokine levels to those of vehicle-treated
controls upon Poly I:C stimulation (Figure 7B and 7C).
Effects of E2 in RL95-2 cells are mediated by ERFigure 5
Effects of E2 in RL95-2 cells are mediated by ER. RL95-
2 cells were plated at 0.2 × 106 cells/well/ml and maintained 
in CD-F12 for 48 hours prior to experiments. Media was 
replaced with media containing vehicle, 10-6 M ICI 182, 780 
(A), or 10-6 M RU486 (B). After 2 hours, media was replaced 
with the indicated combinations of ethanol vehicle, 10-8 M E2, 
10-7 M P, 10-6 M ICI 182, 780, and 10-6 M RU486. Cells 
remained in the indicated media for a total of 66 hours. Cells 
were stimulated with ethanol vehicle, Poly I:C (10 µg/ml), or 
PMA/I (10 ng/ml and 500 ng/ml) 18 hours prior to harvest. A 
total of 100 µl of cell-free supernatant was used to detect IL-
6, IL-8, and IP-10 by ELISA (A, B, and data not shown). Exper-
iments were performed using triplicate wells for each treat-
ment condition and repeated three times. Data 
representative of three experiments are shown. Error bars 
indicate standard deviation of three samples. Statistical signif-
icance (*) was determined by one-way ANOVA and the 
Tukey post-hoc test (P < 0.05).Page 10 of 15
(page number not for citation purposes)
Reproductive Biology and Endocrinology 2005, 3:74 http://www.rbej.com/content/3/1/74
Page 11 of 15
(page number not for citation purposes)
MCF7 cells express functional TLR3Figure 6
MCF7 cells express functional TLR3. Total RNA (100 ng) was used to generate cDNA for measurement of expression of 
TLR3 in MCF7 cells (Lane 1) and RL95-2 cells (Lane 2) (A). The housekeeping gene, GUS, was also included (A). MCF7 cells 
were plated at 0.2 × 106 cells/well/ml and stimulated with vehicle, Poly I:C (10 µg/ml), Poly dI:dC (1 µg/ml), or LPS (100 ng/ml). 
A total of 100 µl cell-free supernatant was used to measure IL-6, IL-8, and IP-10 by ELISA (B). Experiments were performed in 
triplicate and repeated three times. Data shown is representative of three experiments. Error bars indicate standard deviation 
of three samples per treatment condition. Statistical significance (*) was determined by one-way ANOVA and the Tukey post-
hoc test (P < 0.05).
Reproductive Biology and Endocrinology 2005, 3:74 http://www.rbej.com/content/3/1/74Since treatment with antagonists resulted in a decrease in
cell number (data not shown), these results are not due to
the suppression of cytokine and chemokine levels by the
antagonists alone. Had the antagonists caused suppres-
sion of cytokine and chemokine production, the levels of
cytokine and chemokine protein in the antagonist-, hor-
mone-treated samples would have been decreased as
compared to the antagonist-, vehicle-treated samples.
Thus, E2 and P suppress cytokine and chemokine produc-
tion in Poly I:C-stimulated MCF7 cells in a hormone
receptor-dependent manner as was observed in the RL95-
2 cells.
Discussion and conclusion
In this study, we provide the first demonstration that ster-
oid hormones affect TLR function. Specifically, E2 modu-
lates TLR3 function through significant suppression of
Poly I:C-induced proinflammatory and antiviral cytokine
Effects of E2 and P in MCF7 cells are mediated by hormone receptorsFigure 7
Effects of E2 and P in MCF7 cells are mediated by hormone receptors. MCF7 cells were plated at 0.2 × 106 cells/well/
ml and maintained in CD-F12 for 48 hours prior to experiments. Media was replaced with media containing ethanol vehicle 
(A), 10-6 M ICI 182, 780 (B), or 10-6 M RU486 (C). After 2 hours, media was replaced with the indicated combinations of etha-
nol vehicle, 10-8 M E2, 10-7 M P, 10-6 M ICI 182, 780, and 10-6 M RU486. Cells remained in the indicated media for a total of 66 
hours. Cells were stimulated with ethanol vehicle, Poly I:C (10 µg/ml), or PMA/I (10 ng/ml and 500 ng/ml) 18 hours prior to 
harvest. A total of 100 µl of cell-free supernatant was used to detect IL-6, IL-8, and IP-10 by ELISA (A, B, C, and data not 
shown). Experiments were performed in triplicate and repeated three times. Representative data are shown. Error bars indi-
cate standard deviation of three samples. Statistical significance (*) was determined by one-way ANOVA and the Tukey post-
hoc test (P < 0.05).Page 12 of 15
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shown to be dependent on TLR3 in our system[26]. The
suppressive effect is not due to a decrease in the steady
state levels of TLR3 mRNA or protein. However, the inhi-
bition of function is hormone receptor-dependent, as
demonstrated through the use of hormone receptor-posi-
tive and hormone receptor-negative cell lines and the hor-
mone receptor antagonists, ICI 182, 780 and RU486.
The endometrial epithelial cell lines, AN3-CA, HEC-1-A,
KLE, and RL95-2, and the breast adenocarcinoma cell line,
MCF7, differentially express TLR3, ERA, ERB, PRA, and
PRB mRNA. The levels of ERα mRNA in these cell lines
differ quantitatively, with the MCF7 cells demonstrating
the highest quantitative level of ERα mRNA and the HEC-
1A cells not expressing ERα mRNA. All the cell lines uti-
lized, with the exception of the HEC-1A cells, also express
detectable levels of ERα protein. The expression of TLR3 is
noteworthy because expression of TLR3 has not been doc-
umented in the HEC-1-A, KLE, or MCF7 lines. Addition-
ally, MCF7 cells express TLR2, TLR5, and TLR6. The
impact of hormones on signaling of other TLRs, including
those expressed in the MCF7 and RL95-2 cells, has not
been explored and will be the focus of future studies.
We found that E2, but not P, significantly suppresses pro-
duction of both proinflammatory and antiviral cytokines
in Poly I:C-stimulated RL95-2 cells. Both E2 and P sup-
press production of cytokines and chemokines in KLE and
MCF7 cells. Previous reports have demonstrated suppres-
sion of IL-6 mRNA by E2 in cytokine-stimulated and LPS-
stimulated cells[2,36], but other investigators have sug-
gested that IL-6 production is not regulated by ovarian
steroids[16,17]. The data presented in our study suggests
that regulation of the TLR3 signaling pathway by E2 results
in suppression of secreted IL-6, as well as IL-8 and IP-10.
The contradictory findings in the regulation of IL-6 by E2
may be due to variable expression of ER in the tissues
under examination[17]. Additionally, instability of hor-
mone receptor expression in RL95-2 cells has been docu-
mented[37]. In order to address these issues, hormone
receptor expression was verified prior to all experiments in
this study to eliminate the possibility of incorrect observa-
tions due to variable receptor expression. Furthermore, we
have observed that E2 suppression of Poly I:C-stimulated
cytokine production in RL95-2 cells occurs only when
ERα is present.
Significant P effects were observed only in the MCF7 cells.
Although RT-PCR results for the RL95-2 and MCF7 cells in
Table 1 demonstrate that both cell lines express PR, poten-
tial differences in quantitative PR expression may be
present between the cell lines and this may account for the
difference in P effects. However, other investigators have
documented differential efficiency of the two PR isoforms
dependent on cell context [41-43]. Thus, we speculate that
differences between specific cell lines and/or differences
in co-activator and co-repressor expression may underlie
the differences in P action in the two cell lines.
In addition to suppression of IL-6 and IL-8 production, we
demonstrate suppression of IP-10 by E2 in Poly I:C-stimu-
lated RL95-2 cells. E2 has been shown to suppress IP-10
function in murine mammary cells[44]. However, sup-
pression of IP-10 by E2 has not been previously docu-
mented in endometrial cells and tissues. Our findings are
noteworthy due to the presence of TLR3, which recognizes
viral dsRNA, in the endometrium and the role of IP-10 in
the antiviral response. IP-10 may be important in recruit-
ment of immune effector cells and activation of cell sur-
face receptors essential for immune defense against viral
pathogens, such as HIV, CMV, and HSV in the human
endometrium[44,45]. Thus, TLR3 activation and subse-
quent production of IP-10 following dsRNA stimulation
may be a pivotal event in modulating endometrial events.
Although our previous finding of cyclic regulation of TLR3
in the endometrium suggested potential control of TLR3
expression and function by steroid hormones, we found
that E2 does not suppress Poly I:C-induced cytokine and
chemokine production by altering TLR3 mRNA or protein
expression. Thus, our findings in the in vitro model system
suggest that E2 does not directly regulate TLR3 expression,
but does regulate TLR3 function through interaction with
ER. Previous findings suggested that maximal expression
of TLR3 in the endometrium occurs in the mid and late
secretory phases, a time when ERα protein in the endome-
trial epithelium is virtually undetectable [46-48]. Thus,
the suppressive action of E2 on cytokine expression would
serve to suppress TLR3 action at times of low TLR3 expres-
sion. Inhibition of TLR3 function would not occur during
times of maximal TLR3 expression due to lack of ERα. A
similar mechanism of E2 inhibition of expression has
been proposed for the β3 integrin subunit, which is
expressed on endometrial epithelium in a pattern similar
to that observed for TLR3, except with the β3 integrin sub-
unit, E2 inhibits expression rather than function[49].
The exact mechanism by which E2 regulates TLR3 function
remains to be elucidated. Ray and colleagues and Galien
and colleagues demonstrated an inhibition of the DNA-
binding activity of the transcription factors NF-IL6 and
NF-kB by the estrogen receptor, resulting in suppression
of IL-6 gene expression[36,50]. However, the mechanism
of IL-8 and IP-10 suppression has not been explored. IP-
10 production occurs upon activation of the transcription
factor, interferon regulatory factor 3 (IRF3), rather than
NF-κB. Studies examining interactions of IRF3 with ER
have not been performed and will be necessary to deter-
mine if the nature of the suppressive effect of E2 on IP-10Page 13 of 15
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studies will be designed to determine the mechanism by
which E2 regulates TLR3 signaling components.
Suppression of cytokines and chemokines by E2 was deter-
mined to be ER-dependent in this study. Hormone effects
have been shown to be hormone receptor-dependent in
other studies[51]. TLR3-positive endometrial epithelial
cell lines that do not express ERα, such as the HEC-1-A
line, do not exhibit suppressed cytokine and chemokine
production upon stimulation with Poly I:C. Additionally,
treatment of TLR3-positive, ERα-positive cell lines with
the ER antagonist, ICI 182, 780, restores levels of cytokine
and chemokine production to vehicle only levels. All of
the data presented in this study has been obtained using
in vitro experiments with endometrial epithelial cell lines.
We have previously demonstrated that TLR3 is functional
in primary endometrial epithelial cells[26]. Since the
response to E2 and P may be different in primary endome-
trial epithelial cells as compared to endometrial epithelial
cell lines, future experiments will be performed using pri-
mary endometrial epithelial cells to address this question.
Our current and previous studies suggest a role for TLR3
in the endometrium. We have shown TLR3 expression to
be cycle-dependent in primary endometrial epithelial
cells and that the response to Poly I:C in our in vitro sys-
tem requires TLR3[26]. This study demonstrates modula-
tion of TLR3 function by the hormones of the
endometrium. The cytokines and chemokines produced
upon TLR3 ligation are important in normal endometrial
functions and may be crucial in the pathogenesis of
endometrial dysfunctions such as endometriosis [1-4].
Recognition of viral dsRNA by TLR3 and the resulting pro-
duction of inflammatory and antiviral cytokines and
chemokines may be pivotal in the protection of the
endometrium from pathogens. The cyclic regulation of
TLR3 in the endometrium may allow protection against
pathogens while maintaining a system of tolerance
toward the embryo and preventing extensive tissue dam-
age from the inflammatory response. It has been sug-
gested that development of endometrial dysfunction is
characterized by an increased inflammatory environment,
allowing progression of disease[6]. Thus, the influence of
steroid hormones on TLR3 function, specifically the sup-
pression of cytokines and chemokines produced upon
stimulation of TLR3 by dsRNA, may be critical in the reg-
ulation, maintenance, and defense of the human
endometrium.
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